Table 2.
Lesion type | Number of patients (n = 33) | Age (years) (mean ± SD) | CNB/USMT/STMT (N) | Number of biopsies (median [range]) | Follow‐up (days) (mean ± SD)† | Imaging (n) > C‐4a, b (4c)‡ |
---|---|---|---|---|---|---|
ADH | 13 | 48.2 ± 10.5 | 0/3/10 | 4 [2–7] | 976.7 ± 503.0 | 13 (4) |
Pure FEA | 9 | 48.6 ± 12.2 | 0/1/8 | 4 [2–8] | 497.0 ± 134.8 | 9 (3) |
Pure ALH | 3 | 57.7 ± 22.1 | 1/2/0 | 5 [3–9] | 917.0 ± 420.2 | 0 (0) |
ADH + FEA | 8 | 45.9 ± 11.1 | 0/2/6 | 3.5 [2–9] | 841.5 ± 459.1 | 7 (2) |
†Follow‐up data since initial biopsy. At least mammography and/or ultrasonography were examined per year after initial biopsy. ‡Imaging data is by Breast Imaging Reporting and Data System (BI‐RADS) at the initial biopsy. ADH, atypical ductal hyperplasia; ALH, atypical lobular hyperplasia; C, category; CNB, core needle biopsy; FEA, flat epithelial atypia; STMT, stereo‐guided Mammotome biopsy; USMT, ultrasound‐guided Mammotome biopsy.